SEC Form 4 · accession 0001965808-26-000011
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ingrid Delaet
Officer — Chief Regulatory Officer
Period of report
Jul 7, 2026
Accepted (ET)
Jul 9, 2026 · 6:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 7, 2026 | M | 3,401 | $103.52 | A | 19,626 | D | |
| Common StockF2 | Jul 7, 2026 | S | 3,401 | $178.5666 | D | 16,225 | D | |
| Common Stock | Jul 8, 2026 | M | 2,737 | $103.52 | A | 18,962 | D | |
| Common StockF3 | Jul 8, 2026 | S | 2,737 | $178.543 | D | 16,225 | D | |
| Common Stock | Jul 9, 2026 | M | 8,433 | $103.52 | A | 24,658 | D | |
| Common StockF4 | Jul 9, 2026 | S | 8,433 | $178.7187 | D | 16,225 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF5 | $103.52 | Jul 7, 2026 | M | 3,401 | D | — | Feb 13, 2033 | Common Stock | 3,401 | 18,648 | D |
| Non-Qualified Stock OptionF5 | $103.52 | Jul 8, 2026 | M | 2,737 | D | — | Feb 13, 2033 | Common Stock | 2,737 | 15,911 | D |
| Non-Qualified Stock OptionF5 | $103.52 | Jul 9, 2026 | M | 8,433 | D | — | Feb 13, 2033 | Common Stock | 8,433 | 7,478 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $179.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.